Production limitations put a damper on Novo Nordisk's potential growth

Novo Nordisk upgraded its full-year guidance on Friday last week, which raised the ambitions for its GLP-1 drugs in particular -- but the company’s growth has put a strain on its production.

Photo: Novo Nordisk / PR

Danish pharmaceutical firm Novo Nordisk chose to publicize its first quarterly report for 2022 on Friday morning last week, which was a surprise for many, as it came half a week before schedule. The reason for this was a significant upgrade to the company’s expectations for 2022 sales and operating profit.

Novo Nordisk’s sales growth outlook for 2022 has been upgraded to 10–14 percent from a previous 6–10 percent, while the operating growth guidance has been changed to 9–13 percent versus the former estimate of 4–8 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs